Indian pharmaceutical company Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) (BSE:524715) confirmed on Monday that it has completed its merger with Taro Pharmaceutical Industries Ltd (NYSE:TARO), an Israeli research-based pharmaceutical company.
Sun acquired all outstanding Taro shares, making Taro a wholly-owned subsidiary. This strengthens Sun Pharma's position in the competitive generics market by combining their strengths and capabilities.
Sun has been Taro's majority shareholder since 2010.
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars